Bluebird bio Inc

NASDAQ:BLUE  
20.80
+0.41 (+2.01%)
Products

U.S. FDA Approves Bristol-Myers Squibb Co And bluebird bio Inc's Abecma

Published: 03/27/2021 04:26 GMT
Bluebird bio Inc (BLUE) - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and Bluebird Bio’s Abecma (idecabtagene Vicleucel), the First Anti-bcma Car T Cell Therapy for Relapsed Or Refractory Multiple Myeloma.